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Bcl-2 family members are central to the control of cell survival. Work of the last years has established that the function of these proteins
can be regulated by mitogenic signaling cascades. Within the scope of this review, we will discuss the contribution of Bcl-2-dependent
signaling pathways to cell survival by Raf kinases and also address the underlying mechanisms.
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Coordinated cell death is not only important for proper
execution of developmental processes [1] but disturbances
of this process also have far-reaching effects during post-
embryonic life, causing diseases ranging from autoimmune
disorders to cancer. Mutations or changes in expression
levels of prosurvival proteins are commonly associated with
malignant transformation [2]. These alterations may coexist
in tumors with genetic changes in components of the core
death machinery as exemplified by the presence of activat-
ing mutations in B-Raf [3] and inactivating mutations in
Apaf-1 [4] in melanoma. Bcl-2 family members are central
to survival control through their ability to directly affect
mitochondrial events leading to the activation of cell death
caspases [5]. Work of the last years has established that
expression and function of these proteins are under the
control of signaling pathways, which initially have been
uncovered for their role in cellular proliferation, differenti-
ation and transformation, but recently also have been shown
to control cell survival. Within the scope of this review, their
discussion is limited to the prototypical Raf-MEK-ERK0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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cules have also been implicated in survival control and some
of them may either be effectors of this pathway (NF-nB, PI-
3 kinase/Protein kinase B/AKT, Notch), or cooperate with
Raf (JAK/STAT, PI-3 kinase/Protein kinase B/AKT) in
cellular protection [7–9]. Raf kinases control cell survival
to a great extent by targeting members of the Bcl-2 family.
These proteins thus provide a functional link between
control of survival and events governing the cellular demise.
In this review we will summarize the work that established
the connection between the cytosolic serine/threonine
kinases of the Raf family and the suppression of apoptotic
cell death through Bcl-2-dependent and -independent path-
ways. We also discuss the possible mechanisms underlying
survival control by Raf proteins.2. The players: general overview of the apoptosome, Bcl-
2 family proteins, pro- and anti-survival pathways
2.1. The apoptosome and the events leading to its formation
The execution of cells destined to die requires the
activation of a set of cysteine proteases, which because of
their specificity for aspartatic acid are termed cysteine
aspartatic acid specific proteases (caspases) [10]. Numerous
substrates have been identified for these proteolytic
enzymes, which apart from their role in apoptosis also
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tion [12]. Based on their position in the caspase cascade, they
are either termed initiator or effector caspases. Two basic
pathways can be discriminated through which dormant
initiator caspases are triggered. Activation requires that the
proenzymes be brought into close proximity. In the case of
death receptor-initiated cell killing, this is achieved through
the ligand-induced receptor aggregation and recruitment of
death receptor-associated proteins permitting autocatalysis
[13]. Following multiple other death-inducing stimuli such
as growth factor (GF) deprivation, UV, and genotoxic sub-
stances, mitochondria are the primary organelles to respond
to these changes by alterations in the permeability of their
outer membranes. Formation of a functional apoptosome
requires cytochrome c release from the mitochondrial inter-
membrane space, procaspase 9, ATP, and the cytoplasmic
Apaf-1 protein. Cytochrome c binds to Apaf-1, causing an
unfolding and the exposure of the nucleotide binding sites to
ATP. Further conformational changes in Apaf-1 allow olig-
omerization and the exposure of the caspase recruitment
domain (CARD), which binds caspase 9. Stimulation of
caspase 9 activity results from allosteric enhancement
through the apoptosome complex and additionally from
auto-catalytic processing [14]. Effector caspases, once acti-
vated through restricted proteolytic processing by active
caspase 9, produce the apoptotic phenotype accompanying
cell death [10].
Cell survival control targets processes leading to the
activation of caspases by death receptor- and/or mitochon-
dria-initiated stimuli as well as the activated caspases
themselves. As discussed below, both levels of apoptosis
signaling may be susceptible to the regulation by Raf
proteins, implicating the existence of divergent targets of
Raf action.
2.2. Bcl-2 proteins
Bcl-2 proteins comprise a family of evolutionary con-
served proteins with opposing pro- and anti-apoptotic prop-
erties involved in the control of cell survival. The founding
member Bcl-2 was initially discovered because of its
deregulation in the human follicular B cell lymphoma as a
result of a reciprocal chromosomal translocation [15,16]. All
members of this family share the presence of at least one of
four characterized Bcl-2 homology (BH) domains. The BH3
domain contributes much of the cell death-promoting prop-
erties of the proapoptotic Bcl-2 proteins, which is normally
restrained through its interaction with a hydrophobic groove
formed by the BH1-3 domains of prosurvival members of
the family [17]. Heterodimerization of Bcl-2 proteins criti-
cally affects their ability to control cell survival [18]. In
addition, posttranslational modifications as a result of the
activation of death- or survival signaling can result in altered
stability or availability for complex formation, as exempli-
fied by the binding of 14-3-3 proteins and subsequent
relocalization of BAD to the cytoplasm following phos-phorylation by Raf, PKB or protein kinase A (PKA) [19–
21]. In contrast to PKB and PKA, Raf protein kinases have a
very narrow range of substrates (MEK1, -2 and BAD). An
additional N-terminal BH4 domain present in prosurvival
members of the Bcl-2 family associates with C-Raf, a BAD
kinase [19], but also the phosphatase calcineurin, which has
been implicated in the dephosphorylation of BAD [22].
2.3. Bcl-2 interacting proteins
Numerous additional interaction partners for Bcl-2 have
been identified over the years either by screening for bcl-2
related genes or Bcl-2 interacting proteins using the yeast
two-hybrid system or bacteriophage expression libraries
[23]. For many of them the role in survival control by Bcl-
2 has not been delineated. Within the scope of this review we
will limit the discussion of these proteins to C-Raf [24] (see
below) and BAG-1. BAG-1 was initially isolated because of
its interaction with Bcl-2 [25] or the glucocorticoid receptor
[26]. BAG-1 has been shown to bind various cellular targets
including 70-kDa heat shock proteins, C-Raf, components of
the ubiquitylation/proteasome machinery and DNA to regu-
late apoptosis, signaling, proliferation, transcription and cell
motility [27]. Coexpression of BAG-1 with Bcl-2 in Jurkat
cells increased the protection against various cell death
stimuli compared to cells expressing either BAG-1 or Bcl-
2 alone. Increased survival was also seen in BAG-1 express-
ing NIH3T3 cells [25]. BAG-1 interacts with C-Raf in vitro
and in yeast two-hybrid assays [28]. Most strikingly, bacte-
rially produced BAG-1 protein can increase the kinase
activity of C-Raf in vitro independently of Ras [28]. This
interaction may have implications for the activation of
mitochondrial C-Raf (see below).
2.4. Signaling pathways controlling cell survival
Survival of mammalian cells is critically dependent on
the presence of GFs. Withdrawal triggers the mitochondrial
cell death program, whose execution can be significantly
delayed by the expression of Bcl-2 [5]. Analysis of signal-
ing downstream of GF receptors demonstrated the existence
of multiple pathways, whose functions are not limited to
proliferation but are also critical for the process of cell
survival. In the latter case targets have been identified,
which predominantly function in the control of cell survival,
such as Bcl-2 protein and inhibitor of apoptosis proteins
(IAPs). GF-dependent cells can be rendered factor-indepen-
dent by introducing tyrosine kinase oncogenes, mimicking
an activated membrane receptor. The same effect can be
achieved through the combined expression of v-Raf and v-
Myc, whereas expression of an isolated serine/threonine
kinase such as Raf or of the nuclear phosphoprotein Myc
was insufficient to achieve the same effect [29,30]. Dissec-
tion of the contribution of these proteins to GF-indepen-
dence initially suggested that isolated expression of Myc
resulted in enhanced proliferation in the presence of GFs but
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cell cycle progression [31]. Expression of activated Raf on
the contrary delayed the onset of apoptotic cell death [32].
Various pathways have since then been suggested that link
Raf with the prevention of apoptotic cell death, which will
be discussed below.
Several years ago a flurry of papers documented the role
of another Ras effector pathway leading to the activation of
PI-3 kinase (PI3K) and protein kinase B (PKB/AKT) in the
control of cell survival [33,34]. In this process PKB is the
main effector of PI3K and various targets of PKB have been
identified, which are critical for the process of apoptosis
suppression. They range from the Bcl-2 family protein BAD
to transcription factors and proteins involved in the gener-
ation of secondary messengers [33,34].
NF-nB has been reported to promote cell survival and
proliferation in many settings [35], presumably through the
activation of transcriptional targets including members of
the Bcl-2 and IAP families [36]. NF-nB has also been
implicated in the survival control downstream of PKB
[37]. However, although Raf activates NF-nB [38,39], no
role for NF-nB in apoptosis suppression by Raf has been
reported so far. Intriguingly, despite the documented surviv-
al function of NF-nB, activation of Ras and blockade of NF-
nB in the skin resulted in neoplasia [40], suggesting
possible tissue-specific proapoptotic functions of NF-nB
target genes.3. The game: survival control by Raf kinases—role of
Bcl-2-dependent and Bcl-2-independent pathways
3.1. Historical overview
The ability of Raf to suppress apoptosis was first ob-
served in experiments that aimed at defining receptor
downstream signals required for growth and survival. Ex-
pression of oncogenic Raf (gag-v-raf) together with v-Myc
as it is present in the naturally occurring avian retrovirus
MH2 results in synergistic transformation leading to a tumor
spectrum, which is larger than the sum of v-raf- and v-myc-
induced tumors [41] and greatly accelerated tumor growth
[42]. These proteins also synergize in the establishment of
GF-independence [30,43], whereas v-Myc alone accelerates
cell death [31]. Delineation of the Raf contribution to this
synergism revealed that the expression of an oncogenic
form of Raf, gag-v-raf, delayed the onset of apoptotic cell
death in the interleukin 3 (IL-3)-dependent promyeloid cell
line 32D following GF removal [32]. These experiments
also demonstrated that after prolonged GF withdrawal, the
expression of C-Raf became undetectable [32]. We currently
do not know whether this degradation is complete or
generates functional subdomains of the kinase with consti-
tutively active or dominant interfering properties [44].
Genetic evidence for a role of Raf in apoptosis suppres-
sion was provided through the analysis of c-raf-deficientfibroblast cell lines [45] obtained from C-Raf knockout mice
[46] and of c-raf / primary cells [47,48].
3.2. Isozyme-specific functions of Raf kinases in survival
control
Mammalian Raf proteins make up a family of three
closely related kinases characterized by the presence of
three conserved domains (CR) and interspersed variable
regions. CR1 contains the Ras binding domain, important
for the activation of the kinase by GF receptors; CR2
harbors several regulatory threonine and serines residues;
and CR3 represents the catalytic domain of the protein [6].
Analysis of mRNA expression demonstrated ubiquitous
expression of C-Raf with big tissue-specific differences
and a more restricted pattern for A-Raf (epididymis, ovary)
and B-Raf (neuronal tissues) [49]. Isozyme-specific func-
tions for these proteins have been suggested by data
obtained in gene knockout studies [46–48,50–54] and by
the demonstration of differential regulation of their activ-
ities following receptor stimulation [55]. Analysis of iso-
zyme-specific differences in the ability to suppress
apoptosis is still very limited and no direct comparison
between Raf proteins has been carried out. The existence
of isozyme-restricted properties in the regulation of cell
survival has been confirmed by Wiese et al. [56] by
showing that the survival activity of neurotrophins in
motoneurons was critically dependent upon the expression
of B-Raf, which could not be substituted in this function
by C-Raf. Some of the differences may result from the
ability of these isozymes to interact with unique partners
[57], although these data still await confirmation through
genetic analysis. Additionally or possibly as a consequence
of isozyme-specific protein complex formation, Raf kinases
may also display differences in their ability to phosphor-
ylate critical residues on their substrate proteins as exem-
plified by the comparative analysis of serine 112, 136 and
155 phosphorylation on the proapoptotic BAD protein.
Examination of BAD phosphorylation by purified Raf
kinases revealed that B-Raf, like Pak1 kinase [58], targeted
serines 112 and 136, whereas C-Raf was restricted to serine
112 (M. Hekmann, U. Rennefahrt, U.R. Rapp, manuscript
in preparation).
One previously published isozyme-specific interaction
with potential relevance to the process of cell survival
signaling is the binding of A-Raf to hTOM and hTIM,
which are related to components of mitochondrial outer and
inner membrane protein-import receptors from lower organ-
isms. A detailed analysis of A-Raf protein distribution
revealed a selective enrichment of A-but not C-Raf in the
mitochondria [59]. The relevance of this uptake into the
mitochondria for cell survival remains to be demonstrated,
but this finding raises the possibility that the phosphoryla-
tion of mitochondrial proteins involved, e.g. in oxidative
phosphorylation, may provide a new means to Raf kinases
for cell survival control.
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Analysis of survival signaling by Raf very early on
demonstrated the cooperation in this process with the
antiapoptotic protein Bcl-2 [24]. Joint expression of these
proteins in the IL-3-dependent promyeloid cell line 32D
resulted in synergistic apoptosis suppression. Furthermore,
co-immunoprecipitation experiments demonstrated complex
formation between C-Raf and Bcl-2. C-Raf binds to the
BH4 domain of Bcl-2 [19]. Biochemical analysis failed to
demonstrate a substrate–enzyme relationship [24] nor did
expression of v-Raf alter the expression of Bcl-2 [32]. One
consequence of this interaction is that overexpression of
Bcl-2 in 32D cells leads to mitochondrial translocation of C-
Raf. Moreover, a version of activated C-Raf, which resides
in the outer mitochondrial membrane as a result of fusion
with a targeting sequence derived from the p70 Mas protein,
was as efficient in suppression of apoptosis as the combi-
nation of C-Raf and Bcl-2 [19]. One mechanism for survival
signaling at the mitochondria may be the phosphorylation
and thus inactivation of the pro-death member of the Bcl-2
family BAD [19]. Mitochondrial C-Raf is also required for
the protection of endothelial cells from the intrinsic pathway
of apoptosis by basic fibroblast growth factor (bFGF) [60].
3.4. Genetic evidence for Bcl-2/Raf cooperation in tumor
formation
Deregulation of Bcl-2 is frequently observed in tumors
and may contribute to tumor formation by allowing for
survival under conditions of limited GF availability or the
presence of genetic alterations, which normally would result
in the elimination of the damaged cell [2]. Genetic evidence
for a requirement of Bcl-2 in the transformation by Raf was
obtained recently by showing that the loss of Bcl-2 in a
transgenic mouse model for Raf-dependent lung tumor
induction [61] greatly retarded tumor development without
affecting tumor phenotype [62]. Analysis of the affected
tissue confirmed that the increased tumor latency in the
absence of Bcl-2 results primarily from increased apoptosis.
A similar dependence on Bcl-2 was also observed in the
Sos/Ras-dependent transformation of keratinozytes, which
was blocked in EGFR-deficient animals but could be
rescued following expression of a Bcl-2 transgene [63].
3.5. Bcl-2-independent survival control by Raf
Ablation of the c-raf gene in mice resulted in increased
apoptosis of established cell lines derived from knockout
embryos following treatment with various death inducing
stimuli [45]. Protection of these cells could be achieved
either through the introduction of a functional c-raf or bcl-2
gene. Conversely, C-Raf was able to protect Bcl-2-deficient
fibroblasts. Since these cells also lack detectable expression
of Bcl-XS, the only other Bcl-2 family member for which C-
Raf binding had been demonstrated, these data suggest thatC-Raf may have access to survival relevant substrates/
pathways independent of Bcl-2. Although we cannot ex-
clude the contribution of unidentified Bcl-2 family members
interacting with C-Raf, our results clearly demonstrate that
they would not compensate for the lack of Bcl-2 under the
conditions tested [45]. Additional evidence for a Bcl-2
independent survival function of Raf has been suggested
by experiments under conditions, where involvement of
Bcl-2 has not been observed. Work by Erhardt et al. [64]
in the Rat-1 fibroblast system demonstrated that overex-
pression of B-Raf conferred resistance to apoptosis induced
by GF withdrawal or PI-3 kinase inhibition. Whereas
mitochondrial C-Raf suppresses apoptosis in the absence
of detectable ERK activation [19], MEK activity was
essential in this case for protection through B-Raf and
sufficient by itself to achieve the same effect. Contrary to
the situation in 32D cells that were protected by mitochond-
rially active C-Raf against IL-3 withdrawal-induced cell
death [65], B-Raf overexpression in Rat-1 cells did not
interfere with cytochrome c release. We currently lack an
understanding of how B-Raf might interfere with the pro-
cess of cytosolic caspase activation, but as discussed below
this may involve direct interaction of Raf with IAP proteins.
Support for the existence of survival control by Raf
independently of Bcl-2 also has been obtained in Drosoph-
ila. Execution of developmental cell death in the fly utilizes
the same core components described above for mammals. In
addition, the products of three genes, reaper (rpr), hid (head
involution defect) and grim, cooperate in the regulation of
apoptosis in the Drosophila embryo [66]. Analysis of the
human genome failed to reveal homologues genes but the
mammalian apoptosis inducer Smac/Diablo may act as a
functional homolog of Rpr, Hid and Grim [67]. Genetic
analysis in Drosophila showed that the proapoptotic activity
of Hid is suppressed through the Ras-Raf-MEK-MAPK
pathway transcriptionally and posttranslationally (i.e. most
likely through phosphorylation) [68,69].
3.6. Transcriptional regulation of Bcl-2/IAP proteins by Raf
Signaling through Ras-Raf-MEK-ERK has been shown
in Drosophila to contribute to cell survival by interfering
with the function of cell death proteins [68,70]. In the
mammalian system, evidence has been obtained that this
pathway is also active in prosurvival signaling. Apart from
the recruitment of prosurvival signaling through PI3K/PKB-
dependent mechanisms [71], signaling through Raf-MEK-
ERK may up-regulate the expression of prosurvival proteins
of the Bcl-2 and IAP family in a cell type-specific manner:
Bcl-XL expression is increased following stimulation of the
transcriptional regulators ETS2 and NF-nB [72], which
previously have been identified as targets of Raf
[38,39,44,73]. IAP proteins are transcriptionally regulated
by NF-nB [36] and up-regulation has also been observed in
motoneurons following the expression of B-Raf [56]. Raf
signaling may also control cell survival by repression of the
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CC139 fibroblasts reduced Bim expression, abolished con-
formational changes in Bax and blocked the appearance of
apoptotic cells through a MEK/ERK-dependent process
[74].
3.7. Role of additional prosurvival proteins and pathways in
the survival control by Raf or Raf/Bcl-2
3.7.1. IAPs
The IAPs represent a family of structurally related
intracellular proteins, which are well conserved between
species from Drosophila to human [75]. Their antiapoptotic
effects are related to their ability to block active caspases
[76]. We have shown that expression of the chicken IAP
homologue ITA in PC12 cells not only confers resistance to
TNFa- and NGF-withdrawal-induced cell death but also
inhibited the ability of NGF to induce neurite outgrowth
[77]. Co-immunoprecipitation experiments revealed that
ITA binds Raf kinases, both in PC12 cell stable trans-
formants, upon overexpression in 293 and Sf9 cells, and
in the developing chick brain and demonstrated the require-
ment for the BIR domain in this process [77]. To dissect the
role of Raf/IAP interaction in survival and differentiation
control, interaction partners for ITAwere searched in a yeast
two-hybrid screen, which resulted in the identification of a
novel MAGE family protein, NRAGE that also interacts
with the human XIAP proteins [78]. This interaction was
dependent on an intact RING domain in the IAP proteins.
Stable expression of NRAGE in IL-3-dependent 32D cells
caused greatly enhanced cell death with increased binding
of NRAGE to XIAP upon IL-3 withdrawal [78]. BIR
domains of IAP proteins are essential for caspase inhibition,
whereas the RING finger has been implicated in proteinFig. 1. Interaction of NRAGE with XIAP may initiate the destruction of XIAP prot
DIABLO, another regulator of XIAP half-life, functionally interacts with NRAGdegradation of IAP or IAP-associated proteins [76]. These
findings raise the possibility that death stimulus-induced
interaction of NRAGE with XIAP may initiate the destruc-
tion of XIAP, in a fashion that is sensitive to the regulation
by C-Raf (Fig. 1).
3.7.2. PI3K and PKB
Apart form the mitochondrial pathway of apoptosis
suppression by Raf (discussed above), we also could show
that the activity of the immediate downstream effector of
Raf, MEK, is required for the survival of 32D expressing
oncogenic Raf [71]. Mapping of this novel survival pathway
established the requirement for PI3K. The involvement of
one potential PI3K effector, the serine/threonine kinase
PKB, was shown by experiments demonstrating that a
constitutively active mutant of PKB synergizes with onco-
genic C-Raf in apoptosis suppression whereas a dominant
negative mutant blocked survival signaling by MEK. This
pathway may be of particular relevance for the survival
control in transformed cells, as it requires prolonged signal-
ing through the mitogenic cascade. We currently do not
know how Raf signaling leads to activation of PI3K/PKB,
but work in epithelial cells has shown the presence of
autocrine mechanisms triggered through the release of
heparin-binding EGF [79], a transcriptional target down-
stream of ERK [73].
The requirement of MEK kinase activation by Raf for
mouse development and survival signaling has been chal-
lenged recently based on data obtained with mutant mice, in
which endogenous C-Raf had been altered by ‘knockin’
mutations of tyrosines 340/341 to phenylalanine [47]. These
two residues are important for the activation of C-Raf [80].
C-Raf FF mice were indistinguishable from wild-type litter-
mates and mouse embryonic fibroblasts (MEFs) did noteins in a fashion that is sensitive to the regulation by C-Raf; whether SMAC/
E is unknown. UB, ubiquitination.
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death inducers. Since the authors failed to detect MEK
kinase activity in immunoprecipitates of C-Raf FF, they
concluded that activation of MEK by C-Raf is not necessary
for these processes. However, our analysis showed that this
C-Raf mutant retains detectable kinase activity (Rapp,
unpublished data) and thus may function as a hypomorphic
allele of C-Raf comparable in its effect to the residual
protein present in the initially published C-Raf knockout
[46], which shows a comparable phenotype.4. The strategies: mechanisms of Raf- and Raf/Bcl-2-
dependent survival control
Our knowledge of the molecular mechanisms by which
Raf assures cell survival is still very limited. Phosphoryla-
tion inactivation of the proapoptotic protein BAD [19]
provides one potential mechanism for survival control.
Since the expression of this substrate is restricted [5], we
speculate that other BH3 only proteins may also be targets
for Raf regulation. Moreover, Bcl-2-dependent mitochon-
drial translocation of Raf may be most relevant in trans-
formed cells characterized by high levels of Bcl-2
expression, but has to be confirmed in normal cells. These
considerations suggest that major Raf targets may exist for
survival control under normal circumstances.
4.1. Cytoplasmic/mitochondrial targets and their role in
cellular homeostasis
Given the complexity of events preceding caspase acti-
vation, many points of interference are possible at which
Raf kinase may block this process. In addition, Raf may
control cell survival indirectly through its effect on cell
metabolism, the regulation of cell cycle progression, repair
or other processes not directly tied to the execution of
apoptosis.Fig. 2. BAG-1/Hsp70 as initiators of conformational transition involved in actiThe survival activity of Raf originally has been demon-
strated with activated versions of the kinase linked to the
mitochondrial targeting sequence of p70 Mas [19] or to viral
gag [32] including a myristylation motif that attaches Raf to
different membrane compartments in the cell. The discovery
of the Raf-/Bcl-2 interaction suggested a central role for
mitochondrial localization in this process. However, Bcl-2
proteins also reside in other membrane compartment of the
cells [81], and activation of Raf can also occur at the ER
[82] (Fig. 2). Mitochondrial survival control is commonly
seen in the context of maintaining the organelle’s integrity to
prevent leakage of apoptogenic factors [83]. Work in this
area of apoptosis research has been hampered so far by the
failure to unambiguously demonstrate the nature of the pore
through which this leakage occurs or the unequivocal
demonstration of a requirement for such a pore in this
process. The first target implicated in mitochondrial apo-
ptosis control by Raf was the proapoptotic Bcl-2 family
member BAD, which in its non-phosphorylated form het-
erodimerizes with Bcl-2, thereby impeding its antiapoptotic
function. Phosphorylation in the context of potential 14-3-3
binding sites around serines 112 and 136 causes 14-3-3
binding and cytoplasmic relocalization of BAD. In this
scenario, the function of Raf mainly lies in the restoration
of the Bcl-2 function and its ability to assure outer mito-
chondrial membrane integrity.
One mitochondrial protein critical for the exchange of
metabolites between mitochondria and cytoplasm is the
voltage-dependent anion channel (VDAC) [84], which not
only interacts with Bcl-2 but whose function is critically
regulated by Bcl-2 proteins [85]. We recently showed that
VDAC binds to C-Raf independently of Bcl-2 and in vitro
experiments suggested that this interaction leads to a re-
duced reconstitution of VDAC proteins into the outer
mitochondrial membrane, thereby limiting the flow of
metabolites in and out of the mitochondria [65].
Since the survival activity of Raf also extends to post-
mitochondrial events [64], the existence of additional Rafvation of C-Raf at the ER-Golgi and the outer mitochondrial membrane.
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demonstrated that kinase activity is required for apoptosis
suppression by Raf, no evidence has been put forward
suggesting a role for phosphorylation in apoptosome as-
sembly. IAP proteins, which are able to inhibit activated
caspases, also interact with Raf proteins [77]. It is currently
unknown whether this interaction plays a role in the
apoptosis suppression by Raf. As suggested for the apopto-
sis inducing protein NRAGE above, Raf may interfere with
the proteasomal degradation of IAP proteins [86] (Fig. 1).
4.2. Getting to work at the mitochondria
Analysis of survival signaling by C-Raf has stressed the
requirement for the active kinase in this process. So far, we
have no clear understanding how C-Raf gets activated at
the mitochondria or even if C-Raf activation has to occur at
the mitochondria. Normally, activation of C-Raf by GF is
transient as a consequence of dephopshorylation events as
well as separation from proteins such as Ras, which
normally are required to achieve or maintain its full
activity. One possible scenario could be that mitochondrial
localization guards C-Raf proteins against inactivation for
prolonged periods of time. Alternatively, this population
could be a depot for GF recruitment to the plasma
membrane and remains mitochondrial if this flow is inter-
rupted. One protein, which may come into play if C-Raf
activation at the mitochondria occurs, is BAG-1 [27]. As
already discussed, incubation of C-Raf immunoprecipitates
with purified GST-BAG protein was sufficient to activate
the kinase [28]. Thus, it is conceivable that trimolecular
complexes of C-Raf, Bcl-2 and BAG-1 may contain active
mitochondrial C-Raf protein. A role for BAG-1 in the
assembly of a functional signalosome for cell survival was
also suggested by results obtained in BAG-1-deficient
animals. Increased apoptosis in these animals correlated
with the absence of BAD phosphorylation at Ser-136 and
with alterations in intracellular localization of kinases and
expression of genes implicated in mitochondrial apoptosis
control [87].
BAG-1 interacts and regulates the activity of the molec-
ular chaperones Hsp70 and Hsc70 [27]. We suggest that
BAG-1 functions in the process of Raf activation as exchange
factor for Hsp70, which is part of a heat shock protein cycle
that we think is required for the membrane to cytosol
transition of the inactive kinase (as well as conformational
changes of membrane-associated Raf in the case of a GF-
induced activation cycle at the plasma membrane) (Fig. 2).
4.3. Providing the fuel: linking cellular metabolism and
survival
Proliferation and cell survival are strictly dependent upon
sufficient energy supply [88]. The effects of mitogenic
signaling cascades on cellular physiology have been most
thoroughly studied in tumors. Transformed cells frequentlyhave become GF-independent as a result of alterations in
oncogenes and tumor suppressor genes and are no longer
subject to the regulation of cellular processes by extrinsic
factors. Net accumulation of transformed cells results from
both enhanced proliferation and the failure to eliminate
superfluous or damaged cells by apoptosis. Not surprisingly,
many known oncogenes target at least one of these processes.
As first observed byWarburg [89], tumors commonly rely on
glycolysis as a means for energy production. This glycolytic
switch in part is the consequence of the transcriptional up-
regulation of components of the glycolytic machinery
through HIF-dependent and HIF-independent mechanisms
[90]. Additionally, oncogenes may directly affect the activity
of key metabolic enzymes [65,91,92]. The critical role of HIF
in this process is also underscored by the resistance of HIF-
deficient ES cells to teratocarcinoma formation [93].
Published work has suggested a series of events which
precede the onset of apoptosis in GF-dependent cells [88]:
impaired glucose metabolism as a result of glucose trans-
porter down-regulation and a reduction in the flux through the
glycolytic pathway by a direct effect on localization or
activity of glycolytic enzymes; breakdown of the mitochon-
drial membrane potential and release of cytochrome c, drop in
oxygen consumption and mitochondrial membrane potential
[94]. It is to be expected that impaired VDAC function, e.g. as
a result of diminished reconstitution into the outer mitochon-
drial membrane as suggested by our data [86], causes a severe
restriction on the exchange of metabolites between the
mitochondrion and the cytoplasm. In terms of the activity
of prosurvival proteins, different mechanisms may have been
developed to counteract these events: cells protected by Bcl-2
have been shown to adapt to a lower rate of metabolism
following GF removal (decreased mitochondrial membrane
potential, oxygen consumption and glycolysis) [95]. This
decrease in metabolic activity may be caused by the ability of
prosurvival members of the Bcl-2 family tomaintain the outer
mitochondrial membrane integrity by Bcl-2 proteins. Al-
though it is commonly assumed that Bcl-2 family proteins
are important for the ability of PKB to suppress apoptosis
[33] the effects of enforced expression of PKB in GF-
dependent cells differed from those reported for Bcl-2.
PKB was shown to up-regulate GLUT1 expression and
thereby increased glucose uptake, glycolysis, ATP levels
and mitochondrial membrane potential [88]. An increase in
the activity of pyruvate kinase M2, a key enzyme of glycol-
ysis, has been demonstrated in cells transformed by A-Raf
[92,96]. In combination with a decreased mitochondrial flux
as a result of impaired reconstitution of VDAC into the outer
mitochondrial membrane [65], Raf may irreversibly commit
cells to energy production by glycolysis.5. Conclusions and outlook
Results obtained in Raf-deficient animals suggested
that the individual Raf isozymes are rate-limiting for
U.R. Rapp et al. / Biochimica et Biophysica Acta 1644 (2004) 149–158156survival only in a restricted number of tissues [46–
48,53,54,56]. This work also demonstrated the existence
of differences among Raf isozymes in the ability to
suppress apoptosis [56]. Analysis of survival signaling
by Raf so far provided no mechanistic explanation for this
differential behavior. Conceptually this may be the result
of differences in the ability of individual Raf kinases to
function in the signal transduction downstream of recep-
tors for survival factors. Alternatively, interaction with
isozyme-restricted binding partners may determine wheth-
er a Raf kinase has access to substrates critical for cell
survival in a particular tissue.
The delineation of the molecular mechanisms of survival
control by Raf is still in its infancy. Much of the published
work is in support of a critical role for Bcl-2 proteins in this
process by linking Raf kinases to the suppression of
apoptotic cell death. However, evidence has accumulated
for Bcl-2-independent mechanisms, which are even less
defined. Central questions to be answered in the future are
the normal function and regulation of mitochondrial Raf in
this process, the identification of Raf targets in survival
control and the delineation of mechanisms, which determine
isozyme-specific functions of the proteins. Moreover, since
Raf signaling is also critical for the regulation of prolifer-
ation, differentiation and cellular metabolism, future work
will try to gain an understanding for the role of these
processes in the survival control by Raf.References
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